| | HSS - New Treatment Strategies for Systemic Vasculitis (Site not responding. Last check: 2007-11-07) |
 | | I will tell you that in our practice at the Vasculitis Center at the Cleveland Clinic, one of the greatest pitfalls in the management of vasculitis that we see of patients referred into us, are the patients who are "Cytoxan failures." Virtually all of these patients come in with active disease on pulse therapy. |
 | | The primary outcome of this study was the Birmingham Vasculitis Activity Score, which for those of you who are not well familiar with, it is basically an enumeration on a target organ basis of new clinical events that are ascribed by the investigator to be due to vasculitis, not therapy or intercurrent illness. |
 | | Well, the model of using thalidomide in vasculitis is you know ENL, which pathologically is a necrotizing vasculitis in the deep dermis, and it makes it an appealing target. |
| rheumatology.hss.edu /phys/gr/calabrese_lec_tran.asp (7301 words) |